First Trust Nasdaq Pharmaceuticals ETF (FTXH)

NASDAQ: FTXH · IEX Real-Time Price · USD
26.51
+0.14 (0.51%)
Aug 12, 2022 9:42 AM EDT - Market open
0.51%
Assets $44.84M
NAV $26.38
Expense Ratio 0.60%
PE Ratio 16.97
Shares Out 1.70M
Dividend (ttm) $0.24
Dividend Yield 0.89%
Ex-Dividend Date Jun 24, 2022
1-Year Return +0.23%
Volume 2,620
Open 26.34
Previous Close 26.38
Day's Range 26.34 - 26.51
52-Week Low 23.92
52-Week High 28.44
Beta 0.76
Holdings 31
Inception Date Sep 20, 2016

About FTXH

The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depository receipts that comprise the index. The index is designed to provide exposure to U.S. companies comprising the pharmaceutical sector that have been selected based upon their liquidity and weighted based upon their cumulative score on three investing factors: volatility, value and growth. It is non-diversified.

Asset Class Equity
Sector Large Cap
Region North America
Issuer First Trust Portfolios
Stock Exchange NASDAQ
Ticker Symbol FTXH
Index Tracked Nasdaq US Smart Pharmaceuticals Index

Top 10 Holdings

57.42% of assets
Name Symbol Weight
Bristol-Myers Squibb Company BMY 7.98%
Gilead Sciences GILD 7.83%
Johnson & Johnson JNJ 7.65%
AbbVie ABBV 7.10%
Amgen AMGN 6.97%
Vertex Pharmaceuticals VRTX 4.38%
Ironwood Pharmaceuticals IRWD 4.22%
Merck & Co. MRK 3.90%
Pfizer PFE 3.79%
Prestige Consumer Healthcare PBH 3.60%
View More Holdings

Dividends

Ex-Dividend Amount Pay Date
Jun 24, 2022 $0.0384 Jun 30, 2022
Mar 25, 2022 $0.0488 Mar 31, 2022
Dec 23, 2021 $0.1101 Dec 31, 2021
Sep 23, 2021 $0.0393 Sep 30, 2021
Jun 24, 2021 $0.0533 Jun 30, 2021
Mar 25, 2021 $0.0771 Mar 31, 2021
Full Dividend History

News

Pharma ETFs in Focus Post Q1 Earnings

Many industry bigwigs reported solid results with some beating on earnings or revenues or both.

Other symbols: IHEPJPPPHXPH

Solid Q4 Earnings Fail to Impress Pharma ETFs

Solid earnings failed to impress pharma ETFs over the past month due to a broad sell-off in the market.

Other symbols: IHEPJPPPHXPH

Wave of Solid Q3 Earnings Push Pharma ETFs Higher

The slew of Q3 results has led to smooth trading in pharma ETFs over the past month.

Other symbols: IHEPJPPPHXPH

Pharma ETFs Gain on Q2 Earnings

Many industry bigwigs reported solid results with some beating on earnings or revenues or both.

Other symbols: IHEPJPPPHXPH

ETFs to Shine on Pfizer's Impressive COVID-19 Vaccine Update

Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging progress in coronavirus vaccine development as the outbreak worsens.

Other symbols: FDLIEIHIHE

Pharma ETFs in Focus Post Q4 Earnings

Healthcare Q4 results seem robust given that it is the fourth-best sector from a revenue growth look and the sixth-strongest in terms of earnings growth.

Other symbols: IHEPJPPPHXPH

ETFs to Shine as Pfizer's COVID-19 Vaccine Gets a Nod in Europe

Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging progress in coronavirus vaccine development.

Other symbols: DHSFDLHDVIEIH

3 Reasons to Bet on Healthcare ETFs

The broader medical sector should be in the spotlight now on hopes of a coronavirus vaccine and the likelihood of a divided congress.

Other symbols: PJPPPHPSCHXHSXPH

Q3 Earnings Fail to Impress Pharma ETFs

The slew of Q3 results have led to mixed trading in pharma ETFs over the past month.

Other symbols: IHEPJPPPHXPH

Nasdaq Pharmaceuticals ETF (FTXH) Hits a 52-Week High

The First Trust Nasdaq Pharmaceuticals ETF (FTXH) has hit a new 52-week high. Are more gains in store?

Pharma ETFs Soar on Robust Q2 Earnings

Total earnings of 66.4% of the healthcare market capitalization that has reported so far are up 4.4% on revenue growth of 4%.

Other symbols: IHEPJPPPHXPH

COVID-19 Vaccine Push Brings Hope: Stock & ETF Beneficiaries

There are at least a hundred candidates in the COVID-19 vaccine race globally. However, few companies like Moderna, Pfizer and AstraZeneca are showing considerable hope.

ETF Spotlight: Pharmaceuticals driven higher by Pfizer

CNBC'S Morgan Brennan takes a look at pharmaceutical as Pfizer's positive vaccine news has led the sector higher.

Pharma ETFs Gain on Healthy Q4 Earnings

Strong results led to solid trading in pharma ETFs over the past week.

Other symbols: IHEPJPPPHXPH

Pharma ETFs Set to Benefit Post Strong Q3 Earnings

Robust results led to solid trading in pharma ETFs in a month.

Other symbols: IHEPJPPPHXPH

Pharma Q2 Earnings Growth Highest: Time to Buy ETFs?

Despite robust results, pharma ETFs have been trending downward in a month.

Other symbols: IHEPJPPPHXPH

Pharma ETFs Down Despite Solid Q1 Results

Despite such robust results, pharma ETFs have been trending downward in a month.

Other symbols: IHEPJPPPHXPH